Vimal Mehta | Chief Executive Officer |
Richard Steinhart | Chief Financial Officer |
Will Kane | Chief Commercial Officer |
Frank Yocca | Chief Scientific Officer |
Vince O’Neill | Chief Medical Officer |
Reina Benabou | Chief Development Officer |
Geoff Meacham | Bank of America |
Graig Suvannavejh | Goldman Sachs |
Chris Howerton | Jefferies |
Sumant Kulkarni | Canaccord |
Robyn Karnauskas | Truist |
Ram Selvaraju | H.C. Wainwright |
Eddie Hickman | Guggenheim Securities |
Samir Devani | Rx Securities |
Good morning and welcome to the BioXcel Therapeutics Fourth Quarter and Full Year 2020 Financial Results Conference Call. [Operator Instructions] Just to remind everyone, certain matters discussed in today’s conference call and/or answers that maybe given to questions asked are forward-looking statements that are subject to risks and uncertainties relating to future events and/or the future financial performance of the company. Actual results could differ materially from those anticipated in these forward-looking statements. The risk factors that may affect results are detailed in the company’s most recent filings with the U.S. Securities and Exchange Commission, including its quarterly report on Form 10-Q for the quarterly period ended September 30, 2020 as will be updated by its Annual Report on Form 10-K for the year ended December 31, 2020, which can be found on its website, www.bioxceltherapeutics.com or on www.sec.gov.